Status:

COMPLETED

CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events

Lead Sponsor:

Pfizer

Collaborating Sponsors:

Diabetes UK

Department of Health, United Kingdom

Conditions:

Major Coronary Event

Cerebrovascular Accident

Eligibility:

All Genders

40-75 years

Phase:

PHASE4

Brief Summary

A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either...

Eligibility Criteria

Inclusion

  • Patients must have a documented history of at least one of the following:
  • Hypertension (defined as systolic blood pressure 140 mmHg or a diastolic blood pressure 90 mmHg (defined as the disapperance of all sound \[Korotkoff Phase V\] or receiving anti-hypertensive treatment. Blood pressure should be measured after sitting the patient quietly for 3 minutes).
  • Retinopathy (defined as any of the following; non-proliferative retinopathy, pre-pre-proliferative retinopathy, proliferative retinopathy, maculopathy, advanced diabetic eye disease or history of photocoagulation).
  • Microalbuminuria (defined as either, Albumin creatinine ratio \> than = to 2.5 mg/mmol, or Albumin excretion rate on a timed collection \> than = to 20 mcg/min (\> than = to 30 mg/24hrs) on two successive occasions, or a positive micral or other strip test).
  • Macroalbuminuria (defined as either; Albustix or other dipstick evidence of gross proteinuria, Albumin creatinine ratio \> than = to 25 mg/mmol; or Albumin excretion rate on a timed collection \> than = 200 mcg/min (\> than = 300 mg/24hrs) on two sucessive occasions).
  • Current smoker

Exclusion

  • Type I Diabetes Mellitus
  • Any major Coronary event prior to entry into the study

Key Trial Info

Start Date :

January 1 1997

Trial Type :

INTERVENTIONAL

End Date :

February 1 2004

Estimated Enrollment :

2800 Patients enrolled

Trial Details

Trial ID

NCT00327418

Start Date

January 1 1997

End Date

February 1 2004

Last Update

May 10 2007

Active Locations (135)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 34 (135 locations)

1

Pfizer Investigational Site

Fosterhill, Aberdeen, United Kingdom, AB25 2XG

2

Pfizer Investigational Site

Irvine, Ayrshire, United Kingdom, KA12 0AY

3

Pfizer Investigational Site

Midsomer Norton, Bath, United Kingdom, BA3 2UH

4

Pfizer Investigational Site

Reading, Berkshire, United Kingdom, RG2 7AG

CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events | DecenTrialz